ASCO: combo antibody therapy effective for melanoma

May 17, 2013
ASCO: combo antibody therapy effective for melanoma
Concurrent use of two immune checkpoint antibodies -- ipilimumab and nivolumab -- may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in advance of the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in advance of the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Jedd D. Wolchok, M.D., Ph.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues enrolled patients who had received no more than three prior treatments. Patients received intravenous nivolumab and concurrently for four doses, followed by nivolumab alone. Additionally, in two other study arms, patients who had undergone prior ipilimumab treatment received only nivolumab.

The researchers found that, based on the 37 patients treated with concurrent , the objective response rate was 38 percent. In the three concurrent treatment arms that completed the trial, tumor shrinkage rates were 21, 47, and 50 percent, with the highest rates seen in patients treated with the highest dose of both drugs. The responses to therapy were rapid, with three out of four responding patients doing so within the first three months, which is faster than with single-agent ipilimumab. Thirty percent of patients experienced significant of more than 80 percent. Adverse events for concurrent therapy were similar in nature (although some with higher frequency) than those typically seen for the monotherapies and were generally manageable using immunosuppressants.

"The complete and near-complete response rates we're seeing are unprecedented for an in melanoma," Wolchok said in a statement.

Several authors disclosed financial ties to Bristol-Myers Squibb, which funded the study and manufactures ipilimumab and nivolumab.

Explore further: FDA approves new drug for advanced melanoma

More information: Abstract
More Information

Related Stories

FDA approves new drug for advanced melanoma

March 25, 2011

The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade.

Considerable added benefit of ipilimumab in advanced melanoma

November 9, 2012

The humanized antibody ipilimumab (trade name Yervoy) has been approved since August 2011 for the treatment of adult patients with advanced melanoma (black skin cancer) who have already been treated. The term "advanced" means ...

Recommended for you

Oxygen can impair cancer immunotherapy in mice

August 25, 2016

Researchers have identified a mechanism in mice by which anticancer immune responses are inhibited within the lungs, a common site of metastasis for many cancers. This mechanism involves oxygen inhibition of the anticancer ...

Stem cell propagation fuels cancer risk in different organs

August 25, 2016

The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community. Some researchers maintain that environmental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.